Willem J Lesterhuis

List of Publications by Year
in descending order

70	7,285	87888 38	95266 68
papers	citations	h-index	g-index

71	71	71	10054
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesotheliomaâ€"a phase 3 randomised trial. BMJ Open, 2022, 12, e057663.	1.9	9
2	Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy. Frontiers in Oncology, 2022, 12, 849793.	2.8	7
3	Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations. Frontiers in Immunology, 2022, 13, .	4.8	3
4	Malignant Pleural Effusionsâ€"A Window Into Local Anti-Tumor T Cell Immunity?. Frontiers in Oncology, 2021, 11, 672747.	2.8	9
5	A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery. , 2021, 9, e002032.		6
6	Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy. Frontiers in Immunology, 2020, 11, 584423.	4.8	39
7	Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncology, The, 2020, 21, 1213-1223.	10.7	109
8	Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses. Frontiers in Immunology, 2020, 11, 587014.	4.8	56
9	Bilateral murine tumor models for characterizing the response to immune checkpoint blockade. Nature Protocols, 2020, 15, 1628-1648.	12.0	19
10	Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy. Frontiers in Immunology, 2020, 11, 223.	4.8	54
11	Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. Cancer Immunology, Immunotherapy, 2020, 69, 477-488.	4.2	42
12	Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. Science Translational Medicine, 2019, 11, .	12.4	147
13	Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment. OncoImmunology, 2019, 8, e1641390.	4.6	22
14	Functional genomics in cancer immunotherapy: computational approaches for biomarker and drug discovery. Molecular Systems Design and Engineering, 2019, 4, 689-700.	3.4	3
15	Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors. BMC Research Notes, 2018, 11, 864.	1.4	7
16	Combination immune checkpoint blockade as an effective therapy for mesothelioma. OncoImmunology, 2018, 7, e1494111.	4.6	37
17	Transient Treg depletion enhances therapeutic antiâ€cancer vaccination. Immunity, Inflammation and Disease, 2017, 5, 16-28.	2.7	33
18	Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. Nature Reviews Drug Discovery, 2017, 16, 264-272.	46.4	204

#	Article	IF	Citations
19	A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. BMC Cancer, 2017, 17, 684.	2.6	125
20	Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity. Oncotarget, 2017, 8, 54434-54443.	1.8	13
21	Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. OncoImmunology, 2016, 5, e1057673.	4.6	67
22	Chemotherapy and immunotherapy: mapping the road ahead. Current Opinion in Immunology, 2016, 39, 23-29.	5.5	105
23	Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations. Scientific Reports, 2015, 5, 12298.	3.3	63
24	New directions in mesothelioma treatment. Lung Cancer Management, 2015, 4, 299-307.	1.5	1
25	Tumorâ€infiltrating dendritic cells exhibit defective crossâ€presentation of tumor antigens, but is reversed by chemotherapy. European Journal of Immunology, 2015, 45, 49-59.	2.9	64
26	Restoration of defective cross-presentation in tumors by gemcitabine. OncoImmunology, 2015, 4, e1005501.	4.6	16
27	Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen. OncoImmunology, 2015, 4, e1011492.	4.6	26
28	Mouse models of mesothelioma: strengths, limitations and clinical translation. Lung Cancer Management, 2014, 3, 397-410.	1.5	9
29	Comment on â€œDrug Discovery: Turning the Titanicâ€• Science Translational Medicine, 2014, 6, 229le2.	12.4	7
30	Combining chemotherapy and checkpoint blockade in thoracic cancer: how to proceed?. Lung Cancer Management, 2014, 3, 443-457.	1.5	8
31	The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40. BMC Cancer, 2014, 14, 969.	2.6	20
32	Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics. Clinical Cancer Research, 2014, 20, 2831-2837.	7.0	349
33	Chemoimmunotherapy: still waiting for the magic to happen. Lancet Oncology, The, 2014, 15, 780-781.	10.7	5
34	Neoadjuvant anti-tumor vaccination prior to surgery enhances survival. Journal of Translational Medicine, 2014, 12, 245.	4.4	12
35	Immune Stimulatory Features of Classical Chemotherapy. , 2013, , 395-414.		2
36	Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cellâ€“Based Vaccination. Cancer Research, 2013, 73, 19-29.	0.9	131

#	Article	IF	Citations
37	Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells. Clinical Cancer Research, 2013, 19, 1525-1533.	7.0	58
38	Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity. PLoS ONE, 2013, 8, e61895.	2.5	129
39	Programmed Death Ligand 2 in Cancer-Induced Immune Suppression. Clinical and Developmental Immunology, 2012, 2012, 1-8.	3.3	282
40	Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients. Clinical Cancer Research, 2012, 18, 5460-5470.	7.0	86
41	STATing the importance of immune modulation by platinum chemotherapeutics. OncoImmunology, 2012, 1, 234-236.	4.6	31
42	Recovery of symptomatic extravasation of liposomal doxorubicin after dexrazoxane treatment. Anti-Cancer Drugs, 2012, 23, 139-140.	1.4	8
43	Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cellâ€“Based Vaccination in Metastatic Melanoma. Cancer Research, 2012, 72, 6102-6110.	0.9	50
44	The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues. Cancer Immunology, Immunotherapy, 2012, 61, 1101-1111.	4.2	41
45	Cancer immunotherapy â€“ revisited. Nature Reviews Drug Discovery, 2011, 10, 591-600.	46.4	346
46	PD-L2 is predominantly expressed by Th2 cells. Molecular Immunology, 2011, 49, 1-3.	2.2	46
47	Route of Administration Modulates the Induction of Dendritic Cell Vaccineâ€“Induced Antigen-Specific T Cells in Advanced Melanoma Patients. Clinical Cancer Research, 2011, 17, 5725-5735.	7.0	158
48	Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunology, Immunotherapy, 2011, 60, 249-260.	4.2	68
49	Early identification of antigen-specific immune responses in vivo by [¹⁸ F]-labeled 3â€²-fluoro-3â€²-deoxy-thymidine ([¹⁸ F]FLT) PET imaging. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18396-18399.	7.1	65
50	Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. Journal of Clinical Investigation, 2011, 121, 3100-3108.	8.2	271
51	A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. British Journal of Cancer, 2010, 103, 1415-1421.	6.4	60
52	Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients. Clinical Cancer Research, 2010, 16, 5067-5078.	7.0	212
53	Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Research, 2010, 30, 5091-7.	1.1	67
54	Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients. Clinical Cancer Research, 2009, 15, 2531-2540.	7.0	172

#	Article	IF	Citations
55	Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells. Cancer Immunology, Immunotherapy, 2009, 58, 1109-1115.	4.2	25
56	Vascular Endothelial Growth Factor in Systemic Capillary Leak Syndrome. American Journal of Medicine, 2009, 122, e5-e7.	1.5	57
57	Dendritic cell vaccines in melanoma: From promise to proof?. Critical Reviews in Oncology/Hematology, 2008, 66, 118-134.	4.4	113
58	Colitis in an alcohol-dependent woman. Lancet, The, 2007, 369, 2050.	13.7	5
59	In situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients. Cancer Immunology, Immunotherapy, 2007, 56, 1667-1676.	4.2	24
60	Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. International Journal of Cancer, 2006, 120, 978-984.	5.1	82
61	Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Annals of Oncology, 2006, 17, 974-980.	1.2	85
62	Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nature Biotechnology, 2005, 23, 1407-1413.	17.5	791
63	Immunomonitoring Tumor-Specific T Cells in Delayed-Type Hypersensitivity Skin Biopsies After Dendritic Cell Vaccination Correlates With Clinical Outcome. Journal of Clinical Oncology, 2005, 23, 5779-5787.	1.6	174
64	Acute arterial occlusion after chemotherapy for testicular cancer. Lancet Oncology, The, 2005, 6, 910.	10.7	1
65	Dendritic cell immunotherapy: mapping the way. Nature Medicine, 2004, 10, 475-480.	30.7	896
66	Acute generalised exanthematous pustulosis mimicking septic shock. American Journal of Medicine, 2004, 116, 574-575.	1.5	15
67	EBV-related lymphoproliferative disorders in immunocompetent patients. Leukemia, 2003, 17, 2537-2538.	7.2	4
68	Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Research, 2003, 63, 12-7.	0.9	659
69	Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clinical Cancer Research, 2003, 9, 5091-100.	7.0	235
70	Phenotypical and Functional Characterization of Clinical Grade Dendritic Cells. Journal of Immunotherapy, 2002, 25, 429-438.	2.4	140